N/A N=250 Survey to Identify Substance Use in Teenagers and Adolescents
Anesthesia
Primary: Number of Participants With Adolescent and Parent Reported Alcohol, Drug, Vaping and Tobacco Usage — 1; 1; 0; 425 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=3,070 Young Adult Smoker's Treatment Demand
Smoking Cessation
Primary: Program Enrollment — .05 proportion of click-throughs who enroll
N/A N=43 PureWick™ Adolescent Study
Healthy Volunteers, Adolescent
Primary: Performance of the PureWick System in Adolescents After HCP Placement and Self-placement — 90.40; 93.09; 87.15; 90.41 Percentage of urine captured
Phase 2 N=45 Atomoxetine Asian Study in Adult Subjects With Attention-Deficit/Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder
Primary: Discontinuations Due to Adverse Events (AE) — 1; 1 participants
N/A N=48 Written Language Intervention for Adults With Intellectual and Developmental Disabilities
Intellectual Disability · Developmental Disability
Primary: Use of Reading Comprehension Strategies — 3.986; 0.032 reading comprehension strategies used
Phase 4 N=54 Unicirc Adolescent 12-15 Year Old Boys
Circumcision, Male
Primary: Intraoperative Duration — 9.5 minutes
N/A N=24 The Monitoring Study
Type1diabetes
Primary: Percentage of Time Spent With Dexcom CGMG < 60 mg/dl — 1.32; 1.95; 1.05; 0.99 percentage of time
Phase 4 N=445 Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional Outcomes
Attention Deficit Hyperactivity Disorder
Primary: Mean Change in the Conners' Adult ADHD Rating Scale-Investigator Rated: Screening Version (CAARS-Inv:SV) Total ADHD Symptom Score From Baseline to 12 Week Endpoint…
N/A N=14 Contact Lens Insertion and Removal in a Senior Subject Demographic
Visual Acuity
Primary: Overall Success Rate of Insertion and Removal of a Contact Lens — 85.7 Percentage of eyes
Phase 4 N=120 Subject Satisfaction With AbobutulinumtoxinA Treatment
Glabellar Frown Lines
Primary: Subject Satisfaction When Treated With abobutulinumtoxinA in Their Glabellar Lines — 66; 38; 4; 2 Participants
N/A N=8 Sound Processing Innovations in Adult and Paediatric Cochlear Implant Recipients.
Hearing Loss
Primary: Monosyllabic Word in Quiet Scores. — 51; 51.25; 48.50 Percentage of words repeated correctly
Phase 1 N=130 Effects of E-Cigarette Flavors on Adults TCORS 2.0
Nicotine Use Disorder
Primary: Change Score in Liking/Wanting of E-cigarette — -1.06; -5.59; -7.14; -7.63 units on scale
N/A N=29 Electronic Cigarette Use in Young Adult Men and Women
Cigarette Smoking · Tobacco Use
Primary: Contextual Factors Associated With Tobacco Use Episode Reported Via Ecological Momentary Assessment — 3; 22; 11; 12 tobacco use episodes — p=0.002
N/A N=503 Scenario Tailored Opioid Messaging Program (STOMP) to Improve Risk Understanding in Young Adults
Pain, Postoperative · Medication Adherence · Opioid Use
Primary: Opioid Risk Perception — 31.4; 31.1; 32.8; 30.02 score on a scale — p=.001
Phase 2 N=1,363 Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects
Tetanus · Diphtheria · Pertussis
Primary: Number of Participants With Solicited Injections Site or Systemic Reactions Following Vaccination at Day 0: Aged 10-18 Years — 59; 51; 50; 49 Participants
N/A N=16 SaliPen Human Factors Study for OTC Labeling
Xerostomia
Primary: Percentage of Participants Who Appropriately Will Self-select the Study Product for Use Under Simulated OTC Conditions [Phase I] — 100; 100 percentage
N/A N=33 Young Adult Eating Habits
Eating Behavior · Eating Habit
Primary: Change in Brain Response From Baseline to 2-weeks Post High UPF or 2 Weeks no UPF Diet — 0.02; 0.13 arbitrary units
N/A N=25 Nicotine Pharmacokinetic Study of Heated Tobacco and Heated Herbal Products
Healthy Volunteers
Primary: Nicotine Cmax — 13.00; 12.97; 6.00; 6.87 ng/mL
N/A N=18 Atomoxetine/Attention Deficit/ Hyperactive Disorder (ADHD)/Substance Use Disorder (SUD)in a Residential Treatment Facility
Attention Deficit Hyperactivity Disorder
Primary: Change in Adult ADHD Investigator Symptom Rating Scale Score — 17.3 units on a scale
N/A N=32 Developing Rectal USPE Measures for Suppositories (Project DRUM-S)
Microbicide Delivery System Perceptibility and Acceptability
Primary: User Perception Scale Scores — 3.31; 3.36; 2.12; 2.62 units on a scale
N/A N=199 Perceptions of Cigarette Smoking in Young Adults
Smoking, Cigarette
Primary: Subjective Response to Smoking Cigarettes From the Cigarette Evaluation Scale — 4.68; 4.50 score on a scale — p=>.05
Phase 3 N=31 Cool.Click™ Adolescent Transition Study: Study of Saizen® in Subjects With Childhood-onset Growth Hormone Deficiency
Childhood-onset Growth Hormone Deficiency · Pituitary Dwarfism
Primary: Percent Change From Baseline to Week 24 in Trunk Fat — -6.27; -8.36 percent change — p=0.177
N/A N=91 Enhanced SexHealth Intervention to Improve Adolescent Outcomes
Sexually Transmitted Diseases · Reproductive Behavior
Primary: Number of Participants With Uptake of 1 or More Health Services — 43; 33 Participants
N/A N=60 Pharmacokinetic and Subjective Effects of Heated Tobacco Products
Tobacco Use
Primary: Baseline-adjusted Plasma Nicotine Concentration Pharmacokinetic (PK) Parameters [Cmax] Assessment — 6.426; 7.953; 8.288; 7.993 ng/mL
Phase 4 N=123 Safety and Efficacy of Vyvanse in Adults With Attention-Deficit/Hyperactivity Disorder
Attention-Deficit/Hyperactivity Disorder
Primary: Percent of Treatment Failures at up to 6 Weeks — 8.9; 75.0 Percent of participants — p=<0.0001
Phase 2 N=107 An International, Multi-centre, Prospective, Non-controlled, Open, Single-group, 8-week Trial in Adolescent Subjects
Psoriasis Vulgaris
Primary: Adverse Drug Reactions (ADRs) — 2; 1; 1; 1 Number of adverse drug reactions
N/A N=1,257 Effects of FDA Authorized Smokeless Tobacco Claims Among US Adults Who Smoke Cigarettes
Tobacco Product Beliefs and Use
Primary: General Relative Harm Perception — 3.04; 2.76; 2.84; 3.19 score on a scale
Phase 3 N=391 Atomoxetine to Treat Asian Adult Patients With Attention-Deficit/Hyperactivity Disorder
Attention Deficit Hyperactivity Disorder
Primary: Change From Baseline in the Conners' Adult Attention-Deficit/Hyperactivity Disorder Rating Scale-Investigator Rated: Screening Version (CAARS-Inv:SV) 18-Item Total…
N/A N=486 Determining Age Appropriateness of Children's Products and Toys
Healthy Volunteers Only
Primary: Utilization of Toy — .45; .49; .50; .53 Proportion
N/A N=820 Message Testing in Older Adult Smokers
Smoking · Smoking Cessation
Primary: Emotional Response — 2.73; 2.97; 1.26; 2.17 score on a scale